Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Methotrexate pharmacogenomics.

× No keyword cloud information.

11 in total

Review 1. Toward a better understanding of methotrexate.

Authors: Joel M Kremer
Journal: Arthritis Rheum Date: 2004-05

2. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.

Authors: L B Hughes; T M Beasley; H Patel; H K Tiwari; S L Morgan; J E Baggott; K G Saag; J McNicholl; L W Moreland; G S Alarcón; S L Bridges
Journal: Ann Rheum Dis Date: 2006-01-26 Impact factor: 19.103

3. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Authors: A E van Ede; R F Laan; H J Blom; T W Huizinga; C J Haagsma; B A Giesendorf; T M de Boo; L B van de Putte
Journal: Arthritis Rheum Date: 2001-11

4. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.

Authors: C M Ulrich; Y Yasui; R Storb; M M Schubert; J L Wagner; J Bigler; K S Ariail; C L Keener; S Li; H Liu; F M Farin; J D Potter
Journal: Blood Date: 2001-07-01 Impact factor: 22.113

5. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.

Authors: Wako Urano; Atsuo Taniguchi; Hisashi Yamanaka; Eiichi Tanaka; Hiroshi Nakajima; Yuko Matsuda; Hideto Akama; Yutaka Kitamura; Naoyuki Kamatani
Journal: Pharmacogenetics Date: 2002-04

Review 6. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.

Authors: Robert J Kim; Richard C Becker
Journal: Am Heart J Date: 2003-12 Impact factor: 4.749

7. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.

Authors: Thierry Dervieux; Daniel Furst; Diana Orentas Lein; Robert Capps; Katie Smith; Michael Walsh; Joel Kremer
Journal: Arthritis Rheum Date: 2004-09

Review 8. Genetic basis of neural tube defects. II. Genes correlated with folate and methionine metabolism.

Authors: Monika Gos; Agnieszka Szpecht-Potocka
Journal: J Appl Genet Date: 2002 Impact factor: 3.240

Review 9. Pharmacogenetics and folate metabolism -- a promising direction.

Authors: Cornelia M Ulrich; Kim Robien; Rachel Sparks
Journal: Pharmacogenomics Date: 2002-05 Impact factor: 2.533

Review 10. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences.

Authors: B Schwahn; R Rozen
Journal: Am J Pharmacogenomics Date: 2001

5 in total

1. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment.

Authors: Olavio R Baricordi; Marcello Govoni; Roberta Rizzo; Francesco Trotta
Journal: Ann Rheum Dis Date: 2007-08 Impact factor: 19.103

2. Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel.

Authors: Edna Efrati; Hela Elkin; Sagi Nahum; Norberto Krivoy
Journal: Rheumatol Int Date: 2012-07-31 Impact factor: 2.631

3. Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial.

Authors: S Aslibekyan; E E Brown; R J Reynolds; D T Redden; S Morgan; J E Baggott; J Sha; L W Moreland; J R O'Dell; J R Curtis; T R Mikuls; S L Bridges; D K Arnett
Journal: Pharmacogenomics J Date: 2013-04-02 Impact factor: 3.550

4. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons.

Authors: Jose Felix Moruno Manchon; Yuri Dabaghian; Ndidi-Ese Uzor; Shelli R Kesler; Jeffrey S Wefel; Andrey S Tsvetkov
Journal: Sci Rep Date: 2016-05-11 Impact factor: 4.379

5. Effect of the Polymorphism of Folylpolyglutamate Synthetase on Treatment of High-Dose Methotrexate in Pediatric Patients with Acute Lymphocytic Leukemia.

Authors: Zhen Huang; Hong-Fei Tong; Yuan Li; Jiang-Chao Qian; Ju-Xiang Wang; Zhe Wang; Ji-Chen Ruan
Journal: Med Sci Monit Date: 2016-12-17

5 in total